{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:58:26Z","timestamp":1773367106446,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Tremelimumab, an anti\u2010cytotoxic T\u2010lymphocyte antigen\u20104 monoclonal antibody that enhances T\u2010cell activation, was evaluated in a randomized, double\u2010blind, placebo\u2010controlled, phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>b study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meaningful differences in overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>). The objective of this analysis was to evaluate the relationship of exposure with <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>. A population pharmacokinetic (<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>) model adequately described the <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> data. Three factors (sex, C\u2010reactive protein, and baseline tumor size) were identified as statistically significant <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> predictors (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 on clearance). A positive association between exposure and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was observed. However, an association between key baseline factors with <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (regardless of treatment) and imbalances in prognostic factors favoring patients with higher exposure (upper vs. lower <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> quartile) was seen. Taken together, these results suggest that the exposure <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> relationship observed for tremelimumab in mesothelioma is likely spurious rather than a true association of exposure with efficacy.<\/jats:p>","DOI":"10.1111\/cts.12633","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T18:56:12Z","timestamp":1552935372000},"page":"450-458","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exposure\u2013Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status"],"prefix":"10.1111","volume":"12","author":[{"given":"Paul","family":"Baverel","sequence":"first","affiliation":[{"name":"MedImmune  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorin","family":"Roskos","sequence":"additional","affiliation":[{"name":"MedImmune  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasa","family":"Tatipalli","sequence":"additional","affiliation":[{"name":"MedImmune  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Lee","sequence":"additional","affiliation":[{"name":"MedImmune  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Stockman","sequence":"additional","affiliation":[{"name":"AstraZeneca  Macclesfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Taboada","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vicini","sequence":"additional","affiliation":[{"name":"MedImmune  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Horgan","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Narwal","sequence":"additional","affiliation":[{"name":"MedImmune  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.10.1583"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.109"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2033"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6112"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00092-2"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.9.731"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.368"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.309"},{"key":"e_1_2_10_11_1","article-title":"Tremelimumab, a fully human anti\u2010CTLA\u20104 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)","author":"Narwal R.","year":"2015","journal-title":"ASCO"},{"key":"e_1_2_10_12_1","article-title":"Tremelimumab as second\u2010 or third\u2010line treatment of unresectable malignant mesothelioma (MM): results from the global, double\u2010blind, placebo\u2010controlled DETERMINE study","author":"Kindler H.L.","year":"2016","journal-title":"ASCO"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_10_15_1","article-title":"Pharmacokinetics of tremelimumab, a fully human anti\u2010CTLA\u20104 monoclonal antibody, in subjects with unresectable malignant mesothelioma","author":"Calabro L","year":"2014","journal-title":"AACR"},{"key":"e_1_2_10_16_1","volume-title":"NONMEM Users Guides","author":"Beal S.L.","year":"1989"},{"key":"e_1_2_10_17_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2013"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2782590"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1298595"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.628"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.982"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.656"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012445206"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.24"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6852"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30313-3"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T18:22:55Z","timestamp":1694283775000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/cts.12633"],"URL":"https:\/\/doi.org\/10.1111\/cts.12633","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"2018-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}